Lou Bock
Lou Bock is an industry veteran and is focused on identifying emerging biopharmaceutical, device and platform technology companies. Lou sits on the boards of Ascenta Therapeutics, diaDexus, Horizon Therapeutics, Orexigen Therapeutics, SGX Pharmaceuticals and Zogenix. He is responsible for ScaleVP's investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN), and Somaxon (NASDAQ: SOMX). Lou joined Scale Venture Partners in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead's approved antiviral drug, Vistide, and was responsible for the discovery of Gilead's novel thrombin aptamer. Previous to Gilead, he was a research associate at Genentech. Lou holds an M.B.A. from California State University, San Francisco and a B.S. in Biology from California State University, Chico. José A. Cárdenas
José Cárdenas was named Senior Vice President and General Counsel effective January 2009. In addition to serving as chief legal officer of the University, he is responsible for management of ASU Audit & Advisory Services and serves as a University representative on and to the boards of directors of ASU affiliated and related entities such as the ASU Foundation, the Sun Angel Foundation, and the ASU Alumni Association. Mr. Cárdenas also advances and supports the public service and outreach mission of the University by participating in community organizations, representing the University in the business community and before local, regional and state constituencies. Mr. Cárdenas received his BA from the University of Nevada at Las Vegas in 1974. In 1977, he graduated from Stanford University Law School, where he served as an articles editor on the Stanford Law Review. He joined Lewis and Roca in 1978, following a one-year federal district court clerkship. After becoming a partner in the firm in 1982, Cárdenas served in numerous management roles, including as the firm's managing partner (CEO) from 1999 to 2003, at which point he was named the firm's first chairman. Cárdenas has an AV ("Preeminent Attorney") rating from Martindale-Hubbell. He is listed in the 2007, 2008 and 2009 editions of Southwest Super Lawyers in the business litigation category, and in the 2009 edition of The Best Lawyers in America®, by Woodward/White, Aiken, S.C. in the category of commercial litigation. In 1995, he was elected to membership in the prestigious American Law Institute, and he is a member of The Fellows of the American Bar Foundation. Mr. Cárdenas has also been recognized for his many community activities including his selection in 2000 as the recipient of the Mexican government's Ohtli award given to U.S. residents of Mexican descent in recognition of their service to Mexican communities in the United States. He has been admitted to practice law in Arizona, California, the Ninth Circuit Court of Appeals and the United States Supreme Court and is a member of various bar associations including the Hispanic National Bar Association. He has been a member of Los Abogados Hispanic Bar Association since 1978, having served for many years on its board of directors and as president from 1985 to 1988. Augustine V. Cheng
Augie Cheng assumed his post as AzTE’s managing director and chief legal officer in August 2007. Augie came to AzTE from Columbia University, where he was chief counsel of the Patent & Licensing Group in the office of the general counsel. In that capacity, he was responsible for a team of several attorneys and all legal affairs relating to Columbia’s patent protection and licensing programs. He managed several intellectual property lawsuits, including a multi-district patent litigation and other actions, along with related settlements, resulting in hundreds of millions of dollars in returns for Columbia. He has extensive experience in drafting and negotiating agreements in the areas of IP licensing, industry-sponsored research, research consortiums, international collaborations, and inter-institutional agreements. He advised the university administration on policy issues relating to IP, research, and conflicts of interest. During his 13 years at Columbia as associate general counsel, Augie also practiced in the areas of commercial litigation and contracts. He represented Columbia before federal and state agencies on employment claims. Prior to joining Columbia, Augie was in private practice with the New York law firms of Cravath, Swaine & Moore and Schulte Roth & Zabel. He also served as a law clerk to the Honorable William H. Timbers of the United States Court of Appeals for the Second Circuit. Augie received his bachelor’s degree in political science from Columbia University in 1984. After graduation, he worked in the research department of Young & Rubicam, Inc., a marketing communications firm. He attended law school at Fordham University School of Law, where he graduated in 1989 and served as an associate editor of the Fordham Law Review. Michael J. Cleare, Ph.D.
Mike Cleare worked for 30 years at Johnson Matthey, a UK-based multinational world leader in advanced materials technology. His experiences range from the Senior R&D Executive through Business Development to a range of senior business management positions, and included service on the main Board of the Company for four years. While in R&D Mike was involved in the discovery and development of a major new class of anti-cancer drugs (platinum based-particularly carboplatin). He served as President of several of the company's major divisions, including Pharmaceutical Materials, Chemicals and Metals, Catalytic Systems and Electronic Materials. He has managed complex global business, negotiated and closed multi-million dollar licensing and technology transfer deals, and entered into multiple research funding agreements with major universities. From 2000-2007 Mike was the Executive Director of Science and Technology Ventures at Columbia University in New York. This position included responsibility for all technology transfer activities at Columbia and involved licensing, spin off/start up companies, industrial research funding and domestic and international partnerships relating to IP. He reported to the Senior Executive Vice President of Columbia. In August 2007 Mike joined the University of Pennsylvania as Associate Vice Provost for Research, responsible for all technology transfer, IP management and industrial liasion activities. For nine years, Mike was a member of the board of directors of the Canadian biotechnology company, AnorMed, which he helped to spin off from Johnson Matthey in 1996. Mike holds a B. Sc., from MS Imperial College in London and a Ph.D. from London University. Tony Corey (Chair)
In October, 2002 Tony Corey retired as President and CEO of Rodel, Inc. after 5 years with this upcoming semiconductor company. During his tenure, which included the two worst recessions in the history of the semiconductor industry, Rodel witnessed outstanding growth in sales and profits, propelling its valuation from $260 million to over $2 billion during his stewardship. It is valued at more than $3 billion today. Rodel is the global leader in Chemical Mechanical Planerization materials (CMP), a key process to make semiconductor chips. Rodel technology touches almost every chip made in the world today. Rodel was fully acquired by Rohm and Haas in 2002. Prior to Rodel, Tony held many positions of increasing responsibilities around the world with Rohm and Haas ( a $13 Billion company). His assignments took him and his family for ten years overseas in England, Germany, France and Brazil. During his career he worked in the textiles, leather, paper, plastics and coatings industries. His last position at Rohm and Haas was Corporate Vice President and a member of the senior management leadership council. Before entering the corporate world, Tony was a Senior Lecturer at Widener University for two years (Chemical Engineering and Industrial Management). Tony's academic background includes a B.S. in Biology (American University of Beirut), M.S. in Chemical Engineering (The Ohio State University) and M.B.A. (Widener University). He is fluent in English, French, Arabic, Portuguese and adequate in Spanish. Since retirement from the corporate world, Tony has started and co-founded a number of ventures including: Corey Capital (global equity investments), UrbanLogic (real estate development), MtCedar Properties (real estate management) and TradeCom (commodities trading). Tony's community work has focused mainly on education and mentoring young entrepreneurs. Stephen H. Hochschuler, M.D.
Stephen Hochschuler is one of America's leading spine experts. His surgical practices are conducted in Plano, Texas as well as Phoenix, Arizona. Stephen is a Co-Founder of the Texas Back Institute and Chairman of the Board of TBI Holding, Inc. He has published numerous research papers in international spine journals, as well as authored "Back in Shape" (1991) and "Treat Your Back with Surgery" (1998). Stephen graduated from Harvard Medical School and completed an internship and surgery residency at Harvard Surgical Service, Boston City Hospital in Boston, Massachusetts. He completed his orthopedic surgery residency at the University of Texas Southwestern Medical School and Parkland Memorial Hospital in Dallas, Texas. Stephen is a Founding Board Member of the Spine Arthroplasty Society as well as its past president and current Board member. He is an active member of other organizations such as North American Spine Society, American Academy of Orthopedic Surgeons and AOSpine. Stephen also serves in an advisory capacity for several other entities. He is on the Board of Directors of Alphatec Spine, Inc. and is the Chairman of the Board of Directors of SpineMark, Inc. He is on the Scientific Advisory Board of Pioneer Surgical Technologies. Stephen serves on the Business Advisory Board of a number of companies, including Abbott Spine, Orthofix, Inc., BioAssets Development Co, Inc., LDR Spine, DePuy Spine, K2 Medical, Mazor Surgical Technologies and Facet Solutions, Inc. R.F. "Rick" Shangraw, Jr., Ph.D.
Rick Shangraw, Vice President for Research and Economic Affairs for Arizona State University, oversees a $225 million research portfolio for all four ASU campuses. Rick has overall responsibility for research administration, strategic research initiatives, research publications, research space allocations, and economic development activities. Rick's research includes areas such as project risk and uncertainty, decision support systems, and managerial decision making. For the past two years, he has led the Decision Theater at Arizona State University, where he has combined visualization, simulation, and collaboration to address complex issues facing our communities. He holds an appointment with ASU's School of Public Affairs within the College of Public Programs. Prior to joining ASU, Rick was the founder and CEO of Project Performance Corporation (PPC), a research and technology consulting firm specializing in environmental, energy, and information management issues. Clients included the US Department of Energy, US Department of Defense, US Department of Homeland Security, US Environmental Protection Agency, US Department of Interior, and Fortune 500 companies. Under Rick's leadership, the firm grew to more than $30 million in annual revenue with 160 full-time professionals. During his tenture, PPC received the "Inc. 500 Award" for being one of the fastest-growing, privately-held companies in the United States. Prior to PPC, Rick held a tenure-track appointment in the Maxwell School of Citizenship and Public Affairs and the L.C. Smith College of Engineering and Computer Science at Syracuse University. Rick has a B.A., magna cum laude, in Political Science and a Certificate in Environmental Studies from Dickinson College, Carlisle, Pennsylvania; a Master of Public Administration degree from the Maxwell School at Syracuse University; and a Ph.D. from the Maxwell School with a specialization in Technology and Information Policy and Organization Design.
Lou Bock is an industry veteran and is focused on identifying emerging biopharmaceutical, device and platform technology companies. Lou sits on the boards of Ascenta Therapeutics, diaDexus, Horizon Therapeutics, Orexigen Therapeutics, SGX Pharmaceuticals and Zogenix. He is responsible for ScaleVP's investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN), and Somaxon (NASDAQ: SOMX). Lou joined Scale Venture Partners in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead's approved antiviral drug, Vistide, and was responsible for the discovery of Gilead's novel thrombin aptamer. Previous to Gilead, he was a research associate at Genentech. Lou holds an M.B.A. from California State University, San Francisco and a B.S. in Biology from California State University, Chico. José A. Cárdenas
José Cárdenas was named Senior Vice President and General Counsel effective January 2009. In addition to serving as chief legal officer of the University, he is responsible for management of ASU Audit & Advisory Services and serves as a University representative on and to the boards of directors of ASU affiliated and related entities such as the ASU Foundation, the Sun Angel Foundation, and the ASU Alumni Association. Mr. Cárdenas also advances and supports the public service and outreach mission of the University by participating in community organizations, representing the University in the business community and before local, regional and state constituencies. Mr. Cárdenas received his BA from the University of Nevada at Las Vegas in 1974. In 1977, he graduated from Stanford University Law School, where he served as an articles editor on the Stanford Law Review. He joined Lewis and Roca in 1978, following a one-year federal district court clerkship. After becoming a partner in the firm in 1982, Cárdenas served in numerous management roles, including as the firm's managing partner (CEO) from 1999 to 2003, at which point he was named the firm's first chairman. Cárdenas has an AV ("Preeminent Attorney") rating from Martindale-Hubbell. He is listed in the 2007, 2008 and 2009 editions of Southwest Super Lawyers in the business litigation category, and in the 2009 edition of The Best Lawyers in America®, by Woodward/White, Aiken, S.C. in the category of commercial litigation. In 1995, he was elected to membership in the prestigious American Law Institute, and he is a member of The Fellows of the American Bar Foundation. Mr. Cárdenas has also been recognized for his many community activities including his selection in 2000 as the recipient of the Mexican government's Ohtli award given to U.S. residents of Mexican descent in recognition of their service to Mexican communities in the United States. He has been admitted to practice law in Arizona, California, the Ninth Circuit Court of Appeals and the United States Supreme Court and is a member of various bar associations including the Hispanic National Bar Association. He has been a member of Los Abogados Hispanic Bar Association since 1978, having served for many years on its board of directors and as president from 1985 to 1988. Augustine V. Cheng
Augie Cheng assumed his post as AzTE’s managing director and chief legal officer in August 2007. Augie came to AzTE from Columbia University, where he was chief counsel of the Patent & Licensing Group in the office of the general counsel. In that capacity, he was responsible for a team of several attorneys and all legal affairs relating to Columbia’s patent protection and licensing programs. He managed several intellectual property lawsuits, including a multi-district patent litigation and other actions, along with related settlements, resulting in hundreds of millions of dollars in returns for Columbia. He has extensive experience in drafting and negotiating agreements in the areas of IP licensing, industry-sponsored research, research consortiums, international collaborations, and inter-institutional agreements. He advised the university administration on policy issues relating to IP, research, and conflicts of interest. During his 13 years at Columbia as associate general counsel, Augie also practiced in the areas of commercial litigation and contracts. He represented Columbia before federal and state agencies on employment claims. Prior to joining Columbia, Augie was in private practice with the New York law firms of Cravath, Swaine & Moore and Schulte Roth & Zabel. He also served as a law clerk to the Honorable William H. Timbers of the United States Court of Appeals for the Second Circuit. Augie received his bachelor’s degree in political science from Columbia University in 1984. After graduation, he worked in the research department of Young & Rubicam, Inc., a marketing communications firm. He attended law school at Fordham University School of Law, where he graduated in 1989 and served as an associate editor of the Fordham Law Review. Michael J. Cleare, Ph.D.
Mike Cleare worked for 30 years at Johnson Matthey, a UK-based multinational world leader in advanced materials technology. His experiences range from the Senior R&D Executive through Business Development to a range of senior business management positions, and included service on the main Board of the Company for four years. While in R&D Mike was involved in the discovery and development of a major new class of anti-cancer drugs (platinum based-particularly carboplatin). He served as President of several of the company's major divisions, including Pharmaceutical Materials, Chemicals and Metals, Catalytic Systems and Electronic Materials. He has managed complex global business, negotiated and closed multi-million dollar licensing and technology transfer deals, and entered into multiple research funding agreements with major universities. From 2000-2007 Mike was the Executive Director of Science and Technology Ventures at Columbia University in New York. This position included responsibility for all technology transfer activities at Columbia and involved licensing, spin off/start up companies, industrial research funding and domestic and international partnerships relating to IP. He reported to the Senior Executive Vice President of Columbia. In August 2007 Mike joined the University of Pennsylvania as Associate Vice Provost for Research, responsible for all technology transfer, IP management and industrial liasion activities. For nine years, Mike was a member of the board of directors of the Canadian biotechnology company, AnorMed, which he helped to spin off from Johnson Matthey in 1996. Mike holds a B. Sc., from MS Imperial College in London and a Ph.D. from London University. Tony Corey (Chair)
In October, 2002 Tony Corey retired as President and CEO of Rodel, Inc. after 5 years with this upcoming semiconductor company. During his tenure, which included the two worst recessions in the history of the semiconductor industry, Rodel witnessed outstanding growth in sales and profits, propelling its valuation from $260 million to over $2 billion during his stewardship. It is valued at more than $3 billion today. Rodel is the global leader in Chemical Mechanical Planerization materials (CMP), a key process to make semiconductor chips. Rodel technology touches almost every chip made in the world today. Rodel was fully acquired by Rohm and Haas in 2002. Prior to Rodel, Tony held many positions of increasing responsibilities around the world with Rohm and Haas ( a $13 Billion company). His assignments took him and his family for ten years overseas in England, Germany, France and Brazil. During his career he worked in the textiles, leather, paper, plastics and coatings industries. His last position at Rohm and Haas was Corporate Vice President and a member of the senior management leadership council. Before entering the corporate world, Tony was a Senior Lecturer at Widener University for two years (Chemical Engineering and Industrial Management). Tony's academic background includes a B.S. in Biology (American University of Beirut), M.S. in Chemical Engineering (The Ohio State University) and M.B.A. (Widener University). He is fluent in English, French, Arabic, Portuguese and adequate in Spanish. Since retirement from the corporate world, Tony has started and co-founded a number of ventures including: Corey Capital (global equity investments), UrbanLogic (real estate development), MtCedar Properties (real estate management) and TradeCom (commodities trading). Tony's community work has focused mainly on education and mentoring young entrepreneurs. Stephen H. Hochschuler, M.D.
Stephen Hochschuler is one of America's leading spine experts. His surgical practices are conducted in Plano, Texas as well as Phoenix, Arizona. Stephen is a Co-Founder of the Texas Back Institute and Chairman of the Board of TBI Holding, Inc. He has published numerous research papers in international spine journals, as well as authored "Back in Shape" (1991) and "Treat Your Back with Surgery" (1998). Stephen graduated from Harvard Medical School and completed an internship and surgery residency at Harvard Surgical Service, Boston City Hospital in Boston, Massachusetts. He completed his orthopedic surgery residency at the University of Texas Southwestern Medical School and Parkland Memorial Hospital in Dallas, Texas. Stephen is a Founding Board Member of the Spine Arthroplasty Society as well as its past president and current Board member. He is an active member of other organizations such as North American Spine Society, American Academy of Orthopedic Surgeons and AOSpine. Stephen also serves in an advisory capacity for several other entities. He is on the Board of Directors of Alphatec Spine, Inc. and is the Chairman of the Board of Directors of SpineMark, Inc. He is on the Scientific Advisory Board of Pioneer Surgical Technologies. Stephen serves on the Business Advisory Board of a number of companies, including Abbott Spine, Orthofix, Inc., BioAssets Development Co, Inc., LDR Spine, DePuy Spine, K2 Medical, Mazor Surgical Technologies and Facet Solutions, Inc. R.F. "Rick" Shangraw, Jr., Ph.D.
Rick Shangraw, Vice President for Research and Economic Affairs for Arizona State University, oversees a $225 million research portfolio for all four ASU campuses. Rick has overall responsibility for research administration, strategic research initiatives, research publications, research space allocations, and economic development activities. Rick's research includes areas such as project risk and uncertainty, decision support systems, and managerial decision making. For the past two years, he has led the Decision Theater at Arizona State University, where he has combined visualization, simulation, and collaboration to address complex issues facing our communities. He holds an appointment with ASU's School of Public Affairs within the College of Public Programs. Prior to joining ASU, Rick was the founder and CEO of Project Performance Corporation (PPC), a research and technology consulting firm specializing in environmental, energy, and information management issues. Clients included the US Department of Energy, US Department of Defense, US Department of Homeland Security, US Environmental Protection Agency, US Department of Interior, and Fortune 500 companies. Under Rick's leadership, the firm grew to more than $30 million in annual revenue with 160 full-time professionals. During his tenture, PPC received the "Inc. 500 Award" for being one of the fastest-growing, privately-held companies in the United States. Prior to PPC, Rick held a tenure-track appointment in the Maxwell School of Citizenship and Public Affairs and the L.C. Smith College of Engineering and Computer Science at Syracuse University. Rick has a B.A., magna cum laude, in Political Science and a Certificate in Environmental Studies from Dickinson College, Carlisle, Pennsylvania; a Master of Public Administration degree from the Maxwell School at Syracuse University; and a Ph.D. from the Maxwell School with a specialization in Technology and Information Policy and Organization Design.
